252 related articles for article (PubMed ID: 32571377)
1. Measurable residual disease in multiple myeloma: ready for clinical practice?
Burgos L; Puig N; Cedena MT; Mateos MV; Lahuerta JJ; Paiva B; San-Miguel JF
J Hematol Oncol; 2020 Jun; 13(1):82. PubMed ID: 32571377
[TBL] [Abstract][Full Text] [Related]
2. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
[TBL] [Abstract][Full Text] [Related]
3. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.
Rihova L; Vsianska P; Bezdekova R; Kralova R; Penka M; Krejci M; Pour L; Hájek R
Klin Onkol; 2017; 30(Supplementum2):21-28. PubMed ID: 28903567
[TBL] [Abstract][Full Text] [Related]
4. Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.
Soh KT; Tario JD; Hahn TE; Hillengass J; McCarthy PL; Wallace PK
Cytometry B Clin Cytom; 2020 Mar; 98(2):161-173. PubMed ID: 31868315
[TBL] [Abstract][Full Text] [Related]
5. Measurable disease evaluation in patients with myeloma.
Roshal M
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101154. PubMed ID: 32139019
[TBL] [Abstract][Full Text] [Related]
6. MRD Assessment in Multiple Myeloma: Progress and Challenges.
Bertamini L; D'Agostino M; Gay F
Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
[TBL] [Abstract][Full Text] [Related]
7. Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?
Scott SD; Fletcher M; Whitehouse H; Whitby L; Yuan C; Mazzucchelli S; Lin P; de Tute R; Dorwal P; Wallace PK; Tembhare P; Arroz M; Snowden JA; Chantry AD; Barnett D
Cytometry B Clin Cytom; 2019 May; 96(3):201-208. PubMed ID: 30565840
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease analysis in myeloma - when, why and where.
Yanamandra U; Kumar SK
Leuk Lymphoma; 2018 Aug; 59(8):1772-1784. PubMed ID: 29019452
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
[TBL] [Abstract][Full Text] [Related]
10. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
11. Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data.
Sharma P; Singh Sachdeva MU; Varma N; Bose P; Aggarwal R; Malhotra P
J Cancer Res Ther; 2021; 17(6):1515-1520. PubMed ID: 34916387
[TBL] [Abstract][Full Text] [Related]
12. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.
Flores-Montero J; Sanoja-Flores L; Paiva B; Puig N; García-Sánchez O; Böttcher S; van der Velden VHJ; Pérez-Morán JJ; Vidriales MB; García-Sanz R; Jimenez C; González M; Martínez-López J; Corral-Mateos A; Grigore GE; Fluxá R; Pontes R; Caetano J; Sedek L; Del Cañizo MC; Bladé J; Lahuerta JJ; Aguilar C; Bárez A; García-Mateo A; Labrador J; Leoz P; Aguilera-Sanz C; San-Miguel J; Mateos MV; Durie B; van Dongen JJM; Orfao A
Leukemia; 2017 Oct; 31(10):2094-2103. PubMed ID: 28104919
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of the lymphocyte-to-monocyte ratio in multiple myeloma patients with negative minimal residual disease: a single-center retrospective analysis.
Suzuki K; Nishiwaki K; Nagao R; Katori M; Fukushima R; Hattori D; Masuoka H; Yano S
Int J Hematol; 2021 Nov; 114(5):599-607. PubMed ID: 34339005
[TBL] [Abstract][Full Text] [Related]
14. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.
Munshi NC; Avet-Loiseau H; Rawstron AC; Owen RG; Child JA; Thakurta A; Sherrington P; Samur MK; Georgieva A; Anderson KC; Gregory WM
JAMA Oncol; 2017 Jan; 3(1):28-35. PubMed ID: 27632282
[TBL] [Abstract][Full Text] [Related]
15. Deep Response in Multiple Myeloma: A Critical Review.
Fulciniti M; Munshi NC; Martinez-Lopez J
Biomed Res Int; 2015; 2015():832049. PubMed ID: 26783530
[TBL] [Abstract][Full Text] [Related]
16. Ficolled bone marrow is superior to bone marrow buffy coat for detection of minimal residual disease in multiple myeloma.
Bai Y; Chim CS
Hematology; 2019 Dec; 24(1):533-537. PubMed ID: 31280705
[TBL] [Abstract][Full Text] [Related]
17. Multiple Myeloma Minimal Residual Disease.
Paiva B; García-Sanz R; San Miguel JF
Cancer Treat Res; 2016; 169():103-122. PubMed ID: 27696260
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of measurable residual disease in multiple myeloma by multiparametric flow cytometry: Current paradigm, guidelines, and future applications.
Soh KT; Wallace PK
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():43-53. PubMed ID: 34288449
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.
Diamond B; Korde N; Lesokhin AM; Smith EL; Shah U; Mailankody S; Hultcrantz M; Hassoun H; Lu SX; Tan C; Rustad EH; Maura F; Maclachlan K; Peterson T; Derkach A; Devlin S; Landau HJ; Scordo M; Chung DJ; Shah GL; Lahoud O; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Giralt SA; Landgren O
Lancet Haematol; 2021 Jun; 8(6):e422-e432. PubMed ID: 34048681
[TBL] [Abstract][Full Text] [Related]
20. Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma.
Jamet B; Zamagni E; Nanni C; Bailly C; Carlier T; Touzeau C; Michaud AV; Moreau P; Bodet-Milin C; Kraeber-Bodere F
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
